Fungal infections remain hardly treatable because of unstandardized diagnostic tests,
limited antifungal armamentarium, and more specifically, potential toxic interactions between
antifungals and immunosuppressants used during anti-inflammatory therapies, such as
those set up in critically ill COVID-19 patients. Taking into account pre-existing difficulties in
treating vulnerable COVID-19 patients, any co-occurrence of infectious diseases like fungal
infections constitutes a double debacle for patients, healthcare experts, and the public …